The Trump administration’s proposed 340B rebate pilot could mark an important step toward a more accountable — and more affordable — healthcare system.
The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans.
One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market.
Created in 1992, 340B requires drug manufacturers to sell outpatient medicines at steep discounts to certain hospitals and clinics that serve low-income and uninsured patients.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Trump Puts Drug Pricing Program Fraudsters on Notice
Sally C. Pipes
The Trump administration’s proposed 340B rebate pilot could mark an important step toward a more accountable — and more affordable — healthcare system.
The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans.
One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market.
Created in 1992, 340B requires drug manufacturers to sell outpatient medicines at steep discounts to certain hospitals and clinics that serve low-income and uninsured patients.
Read the entire op-ed in Newsmax.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.